Ventricular arrhythmia ablation in the presence of mechanical valve utilization and complications of catheter ablation for ventricular arrhythmia in patients with mechanical prosthetic valves. (31st October 2021)

• Record Type: Journal Article
• Authors: Rozen, Guy; Elbaz‐Greener, Gabby; Andria, Nizar; Heist, E. Kevin; Ruskin, Jeremy N.; Wijeysundera, Harindra C.; Carasso, Shemy; Birati, Edo; Amir, Offer; Marai, Ibrahim
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 32:Number 12(2021)
• Page Start: 3165
• Page End: 3172
• Publication Date: 2021-10-31
• Subjects: catheter ablation -- mechanical valves -- ventricular arrhythmia; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.15271
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Background: Catheter ablation (CA) for ventricular arrhythmias (VAs) is increasingly utilized in recent years. We aimed to investigate the nationwide trends in utilization and procedural complications of CA for VAs in patients with mechanical valve (MV) prosthesis. Methods: We drew data from the US National Inpatient Sample database to identify cases of VA ablations, including premature ventricular contraction and ventricular tachycardia, in patients with MVs, between 2003 and 2015. Sociodemographic and clinical data were collected and the incidence of catheter ablation complications, mortality, and length of stay were analyzed. We compared the outcomes to a propensity‐matched cohort of patients without prior valve surgery. Results: The study population included a weighted total of 647 CA cases in patients with prior MVs. The annual number of ablations almost doubled, from 34 ablations on average during the "early years" (2003–2008) to 64 on average during the "late years" (2009–2015) of the study ( p = .001). Length of stay at the hospital did not differ significantly between patients with MVs and 649 matched patients without prior MVs (5.4 ± 0.4, 4.7 ± 0.3 days, respectively, p = .12). The data revealed a trend toward a higher incidence of complications (12.6% vs. 7.5% respectively, p = .14) and mortality (3.7% vs. 0.7%, respectively, p = .087) among patients with MVs compared to the matched control group, not reaching statistical significance. Conclusion: The data show increased utilization of VA ablations in patients with MVs and a trend toward a higher incidence of in‐hospital mortality and complications compared to the propensity‐matched control group without MVs.